State of the Art Symposium

SA 16 - Imaging of lung cancer in the era of molecular medicine

Lectures

1
Chairperson's introduction

Chairperson's introduction

05:00Annemiek Snoeckx, Zandhoven / BE

2
Genomic testing, targeted and immunotherapy for lung cancer: past, present, and future

Genomic testing, targeted and immunotherapy for lung cancer: past, present, and future

20:00Robin Cornelissen, Rotterdam / NL

3
Assessing lung cancer response to immunotherapy and targeted therapies

Assessing lung cancer response to immunotherapy and targeted therapies

20:00Marie-Pierre Revel, Paris / FR

4
Tumour assessment beyond lesion measurement

Tumour assessment beyond lesion measurement

20:00Helmut Prosch, Vienna / AT

5
Panel discussion: How will lung cancer imaging change in the next five years?

Panel discussion: How will lung cancer imaging change in the next five years?

25:00Panel discussion: How will lung cancer imaging change in the next five years?

5 min
Chairperson's introduction
Annemiek Snoeckx, Zandhoven / Belgium
20 min
Genomic testing, targeted and immunotherapy for lung cancer: past, present, and future
Robin Cornelissen, Rotterdam / Netherlands
1. To get insight in the rapidly evolving field of genomic testing in lung cancer.
2. To get an overview of numerous forms of targeted therapy that are currently available or in development.
3. To understand the mechanisms of resistance on targeted therapy and the different subsequent treatments.
20 min
Assessing lung cancer response to immunotherapy and targeted therapies
Marie-Pierre Revel, Paris / France
1. To understand the difference between RECIST and iRECIST criteria.
2. To recognise immune checkpoint inhibitor pneumonitis.
3. To understand the importance of rebiopsy following progression under targeted therapy.
20 min
Tumour assessment beyond lesion measurement
Helmut Prosch, Vienna / Austria
1. To appreciate the role of contrast enhanced CTs for the evaluation of lung tumours.
2. To understand the potential of MRI for tumour classification.
3. To know the role of modern PET tracers in tumour assessment.
25 min
Panel discussion: How will lung cancer imaging change in the next five years?

PEP Subscription Required

This course is only accessible for ESR Premium Education Package subscribers.

This session offers AI-generated subtitles.